Developments and Implications of New Legislation on Follow-on Biologics
This panel examined current legislative debates concerning the development of regulatory approval processes for follow-on biologics, or large molecule drugs that are created by biological processes, as opposed to medicines created by chemical formulas. The panelists were Peter Hutt, Senior Counsel at Covington & Burling LLP and Lecturer on Law at Harvard Law School, and…